Article

COX-2 inhibitors have potential for treating orbital disease

All patients demonstrated marked improvement of the redness, swelling, and inflammationassociated with thyroid orbitopathy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
Related Content
Handheld fundus camera from Optomed USA launched for use in any care setting
August 2nd 2025

Handheld fundus camera from Optomed USA launched for use in any care setting

3 Things You Should Know About the GA Pipeline
August 2nd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Updates on faricimab for DME from ASRS 2025
August 2nd 2025

Q&A: Updates on faricimab for DME from ASRS 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 2nd 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

EyePoint completes enrollment of LUGANO and LUCIA trials
August 2nd 2025

EyePoint completes enrollment of LUGANO and LUCIA trials

Opus Genetics partners with Global RDH12 Alliance
August 2nd 2025

Opus Genetics partners with Global RDH12 Alliance

© 2025 MJH Life Sciences

All rights reserved.